NCT06792591 is a clinical trial of PEM in Breast Cancer, sponsored by Assiut University.

Who is sponsoring NCT06792591?

NCT06792591 is sponsored by Assiut University.

What drugs are being tested in NCT06792591?

Interventions in NCT06792591: PEM.

What condition does NCT06792591 study?

NCT06792591 studies Breast Cancer.

Is NCT06792591 still recruiting?

NCT06792591 is currently not yet recruiting. Last updated 24 January 2025.

Last reviewed 2025-01-24 · How we verify

NCT06792591

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diagnostic Performance of Positron Emission Mammography in Breast Cancer

Not yet recruiting Last updated 24 January 2025

What this trial tests

trial testing PEM in Breast Cancer in 54 participants. Not yet recruiting.

Timeline

1 February 2025

Primary endpoint
1 September 2026

1 November 2026

Quick facts

Lead sponsor	Assiut University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	54
Start date	1 February 2025
Primary completion	1 September 2026
Estimated completion	1 November 2026

Drugs / interventions tested

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Assiut University

Who can join

Adults 18 to 80, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigate the accuracy of PEM in detection of breast cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06792591 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 24 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06792591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing